|
1) Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation. 1969; 39: 503-15
|
|
|
|
2) National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical practice guidelines for the treatmenr of anemia of chronic renal failure. Am J Kidney Dis. 1997; 30(Supple 3): S192-240
|
|
|
|
|
|
3) US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disases in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and KIidney Diasease: Bethesda, MD, 2006
|
|
|
|
|
|
4) KDDQI: National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006; 47(Suppl 3): S16-85
|
|
|
|
|
|
5) Steinbrook R. Medicare and erythropoietin. N Engl J Med. 2007; 356: 4-6
|
|
|
|
|
6) Besarab A, Bolton WK, Browne JK, et al. The effects of norma as compared with low hematocrit values with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-90
|
|
|
|
|
|
7) FDA ALERT [11/16/2006, Updated 2/16/2007 and 3/09/2007]: FDA Information for Healthcare Professionals, Erythrooiesis Stimulating Agents (ESA) [Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa)], http://www.fda.gov/medwatch/report.htm
|
|
|
|
|
|
8) 2004年版日本透析医学会. ｢慢性血液透析患者における腎性貧血治療ガイドライン｣. 透析会誌. 2004; 37: 1737-63
|
|
|
|
|
|
9) Wilson J, Yao GL, Raftery, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technology Assessment. 2007; 11: 1-220
|
|
|
|
|
|
10) Rizzo JD, LIchtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncl. 2002; 20: 4083-107
|
|
|
|
|
|
11) Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004; 40: 2201-16
|
|
|
|
|
|
12) Kitano T, Tada H, Nishimura T, et al. Prevalence and incidence of anemia in Japanese cancer patients receive in outpatient chemotherapy. Int J Hematol. 2007; 865: 37-41
|
|
|
|
|
|
13) Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369: 381-8
|
|
|
|
|
|
14) Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 366: 2085-9
|
|
|
|
|
|
15) Dureke TB, Loatelli F, Cllyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-84
|
|
|
|
|
|
16) 椿原美冶, 日本透析医学会統計調査委員会. 図説 わが国の慢性透析療法の現状 2006年12月31日現在. 日本透析医学会. 2006
|
|
|
|
|
|
17) Bohlius J, Wilson J, Seidenfield J, et al. Recombinant human erythropoietin and cancer patiens: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98: 708-14
|
|
|
|
|
|
18) Goldberg P. Study more deaths on Aranesp arm in cancer anemia study, no benefit seen [newletter]. The Cancer Letter. 2007; 33: 1
|
|
|
|
|
|
19) Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: How does it affect hemoglobin target？ Kidney Int. 2007; 27: [Epub ahead of print
|
|
|
|
|
|
20) Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999; 33: 821-8
|
|
|
|
|
|
21) Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential？ Semin Dial. 2006; 19: 1-4
|
|
|
|
|
|
22) Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-independent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol. 2007; 292: H2467-74
|
|
|
|
|
|
23) Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotic artery intima-mediated thickness in end-stage renal disease. Circulation. 2002; 106: 2212-7
|
|
|
|
|
|
24) Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Hematology / American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood First Edition paper, prepublished online October 22. 2007; DOI 10. 1182/blood-2007-08-109488
|
|
|
|
|